BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 21315278)

  • 1. Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging.
    Orcutt KD; Slusarczyk AL; Cieslewicz M; Ruiz-Yi B; Bhushan KR; Frangioni JV; Wittrup KD
    Nucl Med Biol; 2011 Feb; 38(2):223-33. PubMed ID: 21315278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha radioimmunotherapy using
    Cheal SM; McDevitt MR; Santich BH; Patel M; Yang G; Fung EK; Veach DR; Bell M; Ahad A; Vargas DB; Punzalan B; Pillarsetty NVK; Xu H; Guo HF; Monette S; Michel AO; Piersigilli A; Scheinberg DA; Ouerfelli O; Cheung NV; Larson SM
    Theranostics; 2020; 10(25):11359-11375. PubMed ID: 33052220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity ⁸⁶Y- or ¹⁷⁷Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates.
    Cheal SM; Xu H; Guo HF; Lee SG; Punzalan B; Chalasani S; Fung EK; Jungbluth A; Zanzonico PB; Carrasquillo JA; O'Donoghue J; Smith-Jones PM; Wittrup KD; Cheung NV; Larson SM
    Eur J Nucl Med Mol Imaging; 2016 May; 43(5):925-937. PubMed ID: 26596724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma.
    Cheal SM; Xu H; Guo HF; Patel M; Punzalan B; Fung EK; Lee SG; Bell M; Singh M; Jungbluth AA; Zanzonico PB; Piersigilli A; Larson SM; Cheung NV
    Theranostics; 2018; 8(18):5106-5125. PubMed ID: 30429889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer.
    Cheal SM; Fung EK; Patel M; Xu H; Guo HF; Zanzonico PB; Monette S; Wittrup KD; Cheung NV; Larson SM
    J Nucl Med; 2017 Nov; 58(11):1735-1742. PubMed ID: 28705917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toward the Optimization of Click-Mediated Pretargeted Radioimmunotherapy.
    Membreno R; Keinänen OM; Cook BE; Tully KM; Fung KC; Lewis JS; Zeglis BM
    Mol Pharm; 2019 May; 16(5):2259-2263. PubMed ID: 30912951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An
    Cheal SM; Patel M; Yang G; Veach D; Xu H; Guo HF; Zanzonico PB; Axworthy DB; Cheung NV; Ouerfelli O; Larson SM
    Bioconjug Chem; 2020 Mar; 31(3):501-506. PubMed ID: 31891487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biodistribution and clearance of small molecule hapten chelates for pretargeted radioimmunotherapy.
    Orcutt KD; Nasr KA; Whitehead DG; Frangioni JV; Wittrup KD
    Mol Imaging Biol; 2011 Apr; 13(2):215-21. PubMed ID: 20533093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complex.
    Cheal SM; Xu H; Guo HF; Zanzonico PB; Larson SM; Cheung NK
    Mol Cancer Ther; 2014 Jul; 13(7):1803-12. PubMed ID: 24944121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of small-molecule-binding affinity on tumor uptake in vivo: a systematic study using a pretargeted bispecific antibody.
    Orcutt KD; Rhoden JJ; Ruiz-Yi B; Frangioni JV; Wittrup KD
    Mol Cancer Ther; 2012 Jun; 11(6):1365-72. PubMed ID: 22491799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of pretargeted monoclonal antibody 2D12.5 and 88Y-Janus-2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) in BALB/c mice with KHJJ mouse adenocarcinoma: a model for 90Y radioimmunotherapy.
    Goodwin DA; Meares CF; Watanabe N; McTigue M; Chaovapong W; Ransone CM; Renn O; Greiner DP; Kukis DL; Kronenberger SI
    Cancer Res; 1994 Nov; 54(22):5937-46. PubMed ID: 7954426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies.
    Lin Y; Pagel JM; Axworthy D; Pantelias A; Hedin N; Press OW
    Cancer Res; 2006 Apr; 66(7):3884-92. PubMed ID: 16585217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to
    Aghevlian S; Lu Y; Winnik MA; Hedley DW; Reilly RM
    Mol Pharm; 2018 Mar; 15(3):1150-1159. PubMed ID: 29314858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phage library-derived human anti-TETA and anti-DOTA ScFv for pretargeting RIT.
    DeNardo SJ; DeNardo GL; Brush J; Carter P
    Hybridoma; 1999 Feb; 18(1):13-21. PubMed ID: 10211783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of hapten-specific scFv from a phage display library and applications for HER2-positive tumor imaging.
    Kim HY; Wang X; Wahlberg B; Edwards WB
    Bioconjug Chem; 2014 Jul; 25(7):1311-22. PubMed ID: 24898150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal Carcinomatosis.
    Chandler CS; Bell MM; Chung SK; Veach DR; Fung EK; Punzalan B; Burnes Vargas D; Patel M; Xu H; Guo HF; Santich BH; Zanzonico PB; Monette S; Nash GM; Cercek A; Jungbluth A; Pandit-Taskar N; Cheung NKV; Larson SM; Cheal SM
    Mol Cancer Ther; 2022 Jan; 21(1):125-137. PubMed ID: 34667111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineered antibody fragments with infinite affinity as reporter genes for PET imaging.
    Wei LH; Olafsen T; Radu C; Hildebrandt IJ; McCoy MR; Phelps ME; Meares C; Wu AM; Czernin J; Weber WA
    J Nucl Med; 2008 Nov; 49(11):1828-35. PubMed ID: 18927335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colon Cancer Xenografts.
    Heskamp S; Hernandez R; Molkenboer-Kuenen JDM; Essler M; Bruchertseifer F; Morgenstern A; Steenbergen EJ; Cai W; Seidl C; McBride WJ; Goldenberg DM; Boerman OC
    J Nucl Med; 2017 Jun; 58(6):926-933. PubMed ID: 28232604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-HLA-DR/anti-DOTA diabody construction in a modular gene design platform: bispecific antibodies for pretargeted radioimmunotherapy.
    DeNardo DG; Xiong CY; Shi XB; DeNardo GL; DeNardo SJ
    Cancer Biother Radiopharm; 2001 Dec; 16(6):525-35. PubMed ID: 11789029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose.
    Förster GJ; Santos EB; Smith-Jones PM; Zanzonico P; Larson SM
    J Nucl Med; 2006 Jan; 47(1):140-9. PubMed ID: 16391198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.